Due to the high prevalence of homozygous SMARCA4 alterations in NSCLC (10–25%) and the potential relevance of this population for SMARCA2 inhibition26–28, we chose to further explore the mutational spectrum of SMARCA4 in NSCLC. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.